Mizuho Securities Reaffirms Their Buy Rating on Elevance Health (ELV)

In a report issued on July 31, Ann Hynes from Mizuho Securities maintained a Buy rating on Elevance Health (ELVResearch Report), with a price target of $545.00. The company’s shares closed last Tuesday at $472.14.

According to TipRanks.com, Hynes is a 5-star analyst with an average return of 9.7% and a 61.9% success rate. Hynes covers the Healthcare sector, focusing on stocks such as AmerisourceBergen, Quest Diagnostics, and Molina Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elevance Health with a $539.27 average price target, representing a 14.2% upside. In a report issued on July 20, Jefferies also maintained a Buy rating on the stock with a $569.00 price target.

See today’s best-performing stocks on TipRanks >>

Elevance Health’s market cap is currently $113B and has a P/E ratio of 18.88.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ELV in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Indiana-based Anthem, Inc. was formed in 2004 after the merger of WellPoint Health Networks Inc. and Anthem, Inc. The company is one of the leading health insurance names, and provides medical benefits through a range of integrated healthcare plans and related services, along with a wide range of specialty products such as life and disability insurance benefits, dental, vision, behavioral health benefit services, as well as long-term care insurance and flexible spending accounts.

Read More on ELV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed